Oncology

Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

December 10, 2007
Susan O’Brien
Susan O’Brien

SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan O’Brien presented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.

ASCO Logo Live Report from ASH:<br />Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

Download this interview

Add podcast to iTunes

Similar Interviews

  • Chronic Lymphocytic Leukemia After Fludarabine Failure

    • John Gribben Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 JOHN

  • Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer

    • Nicholas James Gordon McVie REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer

  • Audio Journal of Oncology 14.2, March 2006

    • Reporting from: American Society of Hematology Meeting, Atlanta, 10-13 December 2005 In this edition: It is not necessary to use rituximab along with

    Post a comment